Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.
There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

Kovsie students’ artworks selected for Absa L’Atelier Awards 2013
2013-03-24

 

Learners from Ferrum High School in Newcastle, KwaZulu-Natal, admiring the artworks at the Centenary gallery.
Photo: Linda Fekisi
24 March 2013

Four artworks by Kovsie students have been selected for the 2013 Absa L’Atelier Awards. The artworks will form part of the national Absa L’Atelier exhibition later this year, which will be held at the Absa Gallery in Johannesburg.

Mandi Bezuidenhout, Louis Kruger and Johannes Botma, all master’s students in Fine Arts, have been selected as finalists for the central region of the prestigious competition.Two artworks of Louis, and one each of Mandi and Johannes, have been selected for the awards. Pauline Gutter, a former Kovsie student, has also been selected as finalist for the central region.

The Absa L’Atelier is South Africa’s most prestigious art competition and is held annually for artists between the ages of 21 and 35. This award not only ensures recognition for South Africa’s emerging artists, but also affords them the opportunity to develop their talents abroad. The winner of last year’s competition, Elrie Joubert, graduated with a master’s in Fine Arts from the UFS in 2010.

Four prizes are available in 2013’s competition. The first prize consists of R125 000 and a residency at the Cité Internationale des Arts in Paris. An Apersand Foundation Residency in New York City and a Sylt Foundation Residency on the Island of Sylt, Germany, will be granted through two merit awards. The most promising artist will receive the Gerard Sekoto Award of R80 000, as well as a residency at the Cité Internationale des Arts in Paris.

The Absa L’Atelier art competition is run in conjunction with the South African National Association for the Visual Arts (SANAVA).

An exhibition of artworks from the central region is currently on display at the Centenary Gallery, upstairs in the Centenary Complex, until 28 March 2013. The gallery will be open on 20, 25, 26, 27, and 28 March from 10:00 to 15:00.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept